Your browser doesn't support javascript.
loading
Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.
Thomson, Stephen A; Banker, Pierette; Bickett, D Mark; Boucheron, Joyce A; Carter, H Luke; Clancy, Daphne C; Cooper, Joel P; Dickerson, Scott H; Garrido, Dulce M; Nolte, Robert T; Peat, Andrew J; Sheckler, Lauren R; Sparks, Steven M; Tavares, Francis X; Wang, Liping; Wang, Tony Y; Weiel, James E.
Affiliation
  • Thomson SA; Metabolic Center for Excellence in Drug Discovery, GlaxoSmithKline, 5 Moore Drive, PO Box 13398, Research Triangle Park, NC 27705, USA. stephen.a.thomson@gsk.com
Bioorg Med Chem Lett ; 19(4): 1177-82, 2009 Feb 15.
Article in En | MEDLINE | ID: mdl-19138846
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Glycogen Phosphorylase / Diabetes Mellitus, Type 2 / Ortho-Aminobenzoates / Hypoglycemic Agents Limits: Animals Language: En Journal: Bioorg Med Chem Lett Journal subject: BIOQUIMICA / QUIMICA Year: 2009 Document type: Article Affiliation country: United States Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Glycogen Phosphorylase / Diabetes Mellitus, Type 2 / Ortho-Aminobenzoates / Hypoglycemic Agents Limits: Animals Language: En Journal: Bioorg Med Chem Lett Journal subject: BIOQUIMICA / QUIMICA Year: 2009 Document type: Article Affiliation country: United States Country of publication: United kingdom